# A Study to Determine Optimal Absorption of Single Dose Omega-3

> **NCT05491759** · PHASE4 · COMPLETED · sponsor: **RDC Clinical Pty Ltd** · enrollment: 22 (actual)

## Conditions studied

- Optimal Gastrointestinal Absorption of Omega-3

## Interventions

- **DRUG:** Product 1 - AquaCelle Fish Oil Triglyceride
- **DRUG:** Product 2 - AquaCelle Fish Oil Ethyl Ester
- **DRUG:** Product 3 - Standard Fish Oil Triglyceride

## Key facts

- **NCT ID:** NCT05491759
- **Lead sponsor:** RDC Clinical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-04
- **Primary completion:** 2022-09-28
- **Final completion:** 2022-09-28
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491759, "A Study to Determine Optimal Absorption of Single Dose Omega-3". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05491759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*